Telaprevir: Difference between revisions

Revision as of 12:35, 11 June 2023 view source Alexander Berchansky (talk \| contribs) 29,726 edits No edit summary ← Older edit		Revision as of 12:40, 11 June 2023 view source Alexander Berchansky (talk \| contribs) 29,726 edits No edit summary Newer edit →
Line 1:		Line 1:
	<StructureSection load='3sv6' size='340' side='right' caption='~~Caption for this~~ structure' scene=''>		<StructureSection load='3sv6' size='340' side='right' caption='Crystal structure of NS3/4A protease in complex with Telaprevir ([[3sv6]])' scene='96/969645/Cv/1'>
	Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3/4A serine protease. See also [https://en.wikipedia.org/wiki/Telaprevir].		Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3/4A serine protease. See also [https://en.wikipedia.org/wiki/Telaprevir].

Navigation menu